Literature DB >> 10546840

Comparative efficacy of intramuscular artemether and intravenous quinine in Nigerian children with cerebral malaria.

P E Olumese1, A Björkman, R A Gbadegesin, A A Adeyemo, O Walker.   

Abstract

The efficacy of a 5-day treatment with intramuscular artemether (3.2-mg/kg loading dose followed by 1.6 mg/kg daily) was compared to that of the standard 7-day treatment with quinine (20-mg/kg loading dose followed by 10 mg/kg every 8 h) in a randomised clinical trial including 103 children aged 12-60 months with cerebral malaria between 1994 and 1996. No statistical difference of immediate efficacy was found between the two treatments. There were 11 (20%) deaths in the artemether group and 14 (28%) in the children who received quinine. The respective artemether versus quinine median fever clearance times (h) were 39 (interquartile ranges [IQ] 30-54) vs. 48 (IQ 30-60), and parasite clearance 42 (IQ 24-60) vs. 36 (IQ 30-48). However, one patient who received artemether had a recrudescence on day 14, which was successfully treated with sulphadoxine-pyrimethamine. Times to recovery from coma were 24 h (IQ 18-45) and 33 h (IQ 19-57), respectively. The occurrence of transient neurological sequelae including motor disabilities, cortical blindness, and afebrile seizures was also similar in the two groups. No adverse reactions to the two drugs were recorded during the study period. Artemether represents an important option in the management of cerebral malaria in Nigeria especially in rural areas where facilities for intravenous administration may not yet be optimal.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10546840     DOI: 10.1016/s0001-706x(99)00031-5

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  9 in total

Review 1.  Artemisinin derivatives versus quinine for cerebral malaria in African children: a systematic review.

Authors:  Hmwe Hmwe Kyu; Eduardo Fernández
Journal:  Bull World Health Organ       Date:  2009-07-30       Impact factor: 9.408

2.  Artemether for severe malaria.

Authors:  Ekpereonne B Esu; Emmanuel E Effa; Oko N Opie; Martin M Meremikwu
Journal:  Cochrane Database Syst Rev       Date:  2019-06-18

Review 3.  Artemisinin derivatives for treating severe malaria.

Authors:  H M McIntosh; P Olliaro
Journal:  Cochrane Database Syst Rev       Date:  2000

4.  Comparative efficacy and safety of the artemisinin derivatives compared to quinine for treating severe malaria in children and adults: A systematic update of literature and network meta-analysis.

Authors:  Nicholas Nyaaba; Nana Efua Andoh; Gordon Amoh; Dominic Selorm Yao Amuzu; Mary Ansong; José M Ordóñez-Mena; Jennifer Hirst
Journal:  PLoS One       Date:  2022-07-20       Impact factor: 3.752

5.  NADPH Oxidase: a Possible Therapeutic Target for Cognitive Impairment in Experimental Cerebral Malaria.

Authors:  Simhadri Praveen Kumar; Phanithi Prakash Babu
Journal:  Mol Neurobiol       Date:  2021-11-16       Impact factor: 5.682

6.  Efficacy of a novel sublingual spray formulation of artemether in African children with Plasmodium falciparum malaria.

Authors:  Daryl Bendel; Stephen Rulisa; Patrick Ansah; Sodiomon Sirima
Journal:  Antimicrob Agents Chemother       Date:  2015-08-24       Impact factor: 5.191

7.  Clinical features and outcome in children with severe Plasmodium falciparum malaria: a meta-analysis.

Authors:  Laurens Manning; Moses Laman; Wendy A Davis; Timothy M E Davis
Journal:  PLoS One       Date:  2014-02-06       Impact factor: 3.240

Review 8.  Artemisinin derivatives versus quinine in treating severe malaria in children: a systematic review.

Authors:  George Praygod; Albie de Frey; Michael Eisenhut
Journal:  Malar J       Date:  2008-10-17       Impact factor: 2.979

Review 9.  Artemether for severe malaria.

Authors:  Ekpereonne Esu; Emmanuel E Effa; Oko N Opie; Amirahobu Uwaoma; Martin M Meremikwu
Journal:  Cochrane Database Syst Rev       Date:  2014-09-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.